Kai J. Bühling
No ORCID on file
· 3 papers in corpus
· active 2009-2014
Study types
- article 3
Condition tags
- dysmenorrhea 1
Frequent coauthors
article
2014
STUDY QUESTION: What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)? SUMMARY ANSWER: The 1 mg/kg/h dose of PDC31 appears to be safe and poten…
article
2010
Dienogest (DNG) has the essential properties of an effective progestogen for use in a new contraceptive pill using estradiol valerate as estrogenic component -- it inhibits ovulation and protects against endometrial proliferation. DNG is a …
article
2009